PRF Technologies (PRFX) Net Income towards Common Stockholders (2020 - 2024)
PRF Technologies (PRFX) posted quarterly Net Income towards Common Stockholders of -$7.6 million for Q2 2024, down 204.12% year-on-year from $7.3 million in Q3 2023, and down 30.63% on a QoQ basis from -$5.8 million in Q1 2024.
PRF Technologies (PRFX) Net Income towards Common Stockholders (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Net Income towards Common Stockholders for 5 consecutive years, with -$7.6 million the latest figure, recorded in Q2 2024.
- Quarterly Net Income towards Common Stockholders fell 204.12% year-over-year to -$7.6 million in Q2 2024, while the trailing twelve-month figure through Dec 2025 was -$7.6 million (up 68.54% YoY) and the FY2025 annual result came in at -$5.0 million, up 66.16% from the prior year.
- Net Income towards Common Stockholders slipped to -$7.6 million in Q2 2024 per PRFX's latest filing, from -$5.8 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for PRFX reached as high as -$700000.0 in Q3 2020 and fell as low as -$10.7 million in Q4 2023.
- A 5-year average of -$3.7 million and a median of -$2.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 31.46% — and 2024, when it tumbled 204.12%.
- Year by year, Net Income towards Common Stockholders stood at -$4.2 million in 2020, then sank by 65.42% to -$6.9 million in 2021, then decreased by 28.75% to -$8.9 million in 2022, then retreated by 21.01% to -$10.7 million in 2023, then rose by 29.24% to -$7.6 million in 2024.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$7.6 million, -$5.8 million, and -$10.7 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | PRF Technologies | 706,290.59 | -3.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -7.60 Mn |
| Mar 31, 2024 | -5.82 Mn |
| Dec 31, 2023 | -10.74 Mn |
| Sep 30, 2023 | -1.60 Mn |
| Jun 30, 2023 | -2.50 Mn |
| Mar 31, 2023 | -2.66 Mn |
| Dec 31, 2022 | -8.88 Mn |
| Sep 30, 2022 | -2.34 Mn |
| Jun 30, 2022 | -2.08 Mn |
| Mar 31, 2022 | -1.91 Mn |
| Dec 31, 2021 | -6.89 Mn |
| Sep 30, 2021 | -2.00 Mn |
| Jun 30, 2021 | -1.88 Mn |
| Mar 31, 2021 | -2.04 Mn |
| Dec 31, 2020 | -4.17 Mn |
| Sep 30, 2020 | -700,000.00 |
| Jun 30, 2020 | -969,000.00 |
| Mar 31, 2020 | -1.59 Mn |